It is with great honur and enthusiasm that I continue my mandate as Chief Scientific Officer of Inbiotics. Over the last 5 years, sustained investment on the various domain of Inbiotics to nourish our major divisions viz drug inlicensing, technology transfer, diagnostics, R&D; which has enabled the creation of a solid base of research unit of good standards.

Inbiotics has many challenges to face if it wishes to continue to stand out in the society of modern science: it needs to revitalize research and innovation by fostering major cross-sectoral projects and knowledge transfer to businesses, practice settings and public bodies; improve the competitiveness of Inbiotics researchers both within and abroad; and provide increased support to our young scientists.